Group 1 - The core viewpoint of the article highlights the successful debut of Haixi New Drug on the Hong Kong Stock Exchange, marking it as the first pharmaceutical company from Fujian to enter the Hong Kong market [1] - Haixi New Drug opened at 102 HKD, a rise of 18.06% from its issue price of 86.4 HKD, and closed at 104.2 HKD, representing a total increase of 20.6% [1] - The company's market capitalization reached 7.003 billion HKD following its first trading day [1] Group 2 - Haixi New Drug operates as a comprehensive biopharmaceutical enterprise, focusing on both generic and innovative drugs, with a robust product pipeline in various therapeutic areas including oncology and respiratory diseases [1] - The company has received approval for 15 generic drugs and has 4 innovative drugs in development, along with 37 global patents, showcasing its strong R&D capabilities [1] - The establishment of Haixi New Drug is part of a broader initiative by Fujian Province to develop its biopharmaceutical industry, which has been designated as a strategic emerging industry since 2009 [2]
海西新药在港交所上市